AZTA · Azenta, Inc.
Market Cap
$1.44B
Shares
43.81M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$593.82M
+3.6%
FY2025
Net Income
-$55.76M
+66.2%
FY2025
Gross Margin
45.52%
+1.1pp
FY2025
Operating Margin
-4.52%
+4.4pp
FY2025
Diluted EPS
-$1.22
+60.6%
FY2025
Operating Cash Flow
$72.18M
+45.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $613M – $618M | $613.81M | $593.82M | $573.45M | $551.49M | $555.5M | $513.7M | $388.54M | $334.18M | $631.56M | $527.5M | $434.01M | $552.71M | $482.85M | $422.44M | $488.98M | $688.11M | $592.97M | $218.71M | |
| — | $343.44M | $323.54M | $318.83M | $312.28M | $299.91M | $269.89M | $216.39M | $199.58M | $385.48M | $425.48M | $362.24M | $363.6M | $315.51M | $290.13M | $329.53M | $465.08M | $426.68M | $224.7M | |
| — | $270.37M | $270.28M | $254.62M | $239.21M | $255.58M | $243.81M | $172.15M | $134.6M | $246.08M | $198.89M | $156.69M | $189.11M | $167.34M | $132.31M | $159.45M | $223.02M | $166.3M | -$6M | |
| — | — | 45.52% | 44.4% | 43.38% | 46.01% | 47.46% | 44.31% | 40.28% | 38.96% | 37.7% | 36.1% | 34.21% | 34.66% | 31.32% | 32.61% | 32.41% | 28.04% | -2.74% | |
| — | $35.73M | $30.39M | $31.52M | $32.14M | $27.54M | $22.41M | $17.82M | $17.32M | $46.94M | $39.88M | $44.24M | $52.23M | $52.65M | $46.21M | $44.72M | $39.85M | $31.16M | $31.61M | |
| — | $257.38M | $261.56M | $262.96M | $263.74M | $251.47M | $252.1M | $190.26M | $163.33M | $167.02M | $141.55M | $119.29M | $115.27M | $111.1M | $96.52M | $97.98M | $102.54M | $85.6M | $91.23M | |
| — | $22.7M | $24.4M | $28.6M | $32.1M | $32.3M | $37.4M | $35.4M | $27.3M | $24.2M | $17.1M | $14.8M | $12.9M | $10.6M | $9.8M | $6.7M | $4.6M | $3.9M | — | |
| — | $55.66M | $61.21M | $90.74M | $85.58M | $53.7M | $65.33M | $65.5M | $54.45M | $37.43M | $28.15M | $28.05M | $25.16M | $23.46M | $24.16M | $21.62M | $17.25M | $18.42M | $25.86M | |
| — | $3.48M | $5.17M | $6.77M | $4.58M | $712K | $385K | $674K | $1.39M | $714K | $3.14M | $10.21M | $4.71M | $6.29M | $6.29M | $3.28M | $1.04M | $2.53M | $12.81M | |
| — | $445.68M | $297.12M | $305.91M | $300.46M | $280.32M | $274.9M | $208.75M | $182.04M | $214.67M | $184.57M | $173.74M | $172.22M | $170.04M | $149.11M | $157.81M | $143.42M | $119.29M | $222.03M | |
| — | -$175.3M | -$26.84M | -$51.28M | -$61.25M | -$24.74M | -$31.09M | -$36.6M | -$47.43M | $31.41M | $14.32M | -$17.05M | $16.89M | -$2.7M | -$16.8M | $1.64M | $79.6M | $47.01M | -$228.03M | |
| — | — | -4.52% | -8.94% | -11.11% | -4.45% | -6.05% | -9.42% | -14.19% | 4.97% | 2.71% | -3.93% | 3.06% | -0.56% | -3.98% | 0.34% | 11.57% | 7.93% | -104.26% | |
| — | -$119.64M | $34.37M | $39.46M | $24.34M | $28.97M | $34.24M | $28.9M | $7.02M | $68.84M | $42.47M | $10.99M | $42.05M | $20.76M | $7.36M | $23.26M | $96.85M | $65.43M | -$202.17M | |
| — | $4.18M | — | — | — | $4.59M | $2.04M | $2.94M | $22.25M | $9.52M | $408K | $157K | $395K | $202K | $2000 | $14K | $65K | $80K | $454K | |
| — | — | — | $33.18M | $43.74M | $15.7M | — | — | — | — | — | $452K | $899K | $950K | $1.03M | $1.21M | $1.15M | $1.12M | $2.72M | |
| — | $4.72M | $922K | -$732K | -$2.3M | -$898K | -$16.48M | -$1.6M | -$1.39M | -$3.3M | -$1.7M | -$1.38M | $421K | $256K | $1.23M | $660K | $1.88M | $367K | $31K | |
| — | -$2.77M | — | — | — | — | — | — | — | — | -$453K | -$1.07M | -$164K | $1.24M | $2.44M | $2.13M | $4.82M | $1.07M | $33K | |
| — | -$152.26M | -$7.14M | -$19.13M | -$20.01M | -$9.94M | -$48.97M | -$40.29M | -$83.96M | $20.47M | $14.52M | -$18.14M | $17.82M | -$1.7M | -$14.54M | $3.5M | $127.58M | $56.06M | -$226.92M | |
| — | -$40.17M | -$31.6M | $5.24M | -$11.97M | $1.35M | -$20.1M | -$13.93M | -$22.83M | -$47.25M | $3.38M | $66.25M | $3.43M | -$1.98M | -$4.99M | -$126.2M | $1.95M | -$2.75M | $643K | |
| — | -$122.9M | -$55.76M | -$164.9M | -$14.64M | $2.13B | $110.75M | $64.85M | $437.42M | $116.58M | $62.61M | -$69.48M | $14.22M | $31.36M | -$2.22M | $136.79M | $130.39M | $59.84M | -$227.61M | |
| — | — | -9.39% | -28.76% | -2.65% | 383.95% | 21.56% | 16.69% | 130.89% | 18.46% | 11.87% | -16.01% | 2.57% | 6.5% | -0.52% | 27.97% | 18.95% | 10.09% | -104.07% | |
| — | — | — | — | — | — | — | — | — | $111K | — | $0 | $0 | $161K | $65K | $46K | $52K | $43K | $85K | |
| — | -$122.9M | -$55.76M | -$164.9M | -$14.64M | $2.13B | $110.75M | $64.85M | $437.42M | $116.58M | — | — | — | — | — | — | — | — | — | |
| — | -$131.72M | -$64.51M | -$115.94M | $6.85M | $2.03B | $108.18M | $83.26M | $427.34M | $114.95M | $62.66M | -$60.21M | $4.43M | $24.44M | -$3.25M | $143.11M | $129.84M | — | — | |
| USD/shares | — | -$2.67 | -$1.22 | -$3.10 | -$0.22 | $28.48 | $1.49 | $0.88 | $6.08 | $1.65 | $0.90 | -$1.01 | $0.21 | $0.47 | -$0.03 | $2.10 | $2.02 | $0.94 | -$3.62 |
| USD/shares | — | -$2.67 | -$1.22 | -$3.10G | -$0.22 | $28.48 | $1.49 | $0.88 | $6.04 | $1.64 | $0.89 | -$1.01 | $0.21 | $0.46 | -$0.03 | $2.08 | $2.01 | $0.93 | -$3.62 |
| shares | — | — | 45.74M | 53.18M | 66.25M | 74.9M | 74.23M | 73.56M | 71.99M | 70.49M | 69.58M | 68.51M | 67.41M | 66.65M | 65.91M | 65.13M | 64.55M | 63.78M | 62.91M |
| shares | — | — | 45.9M | 53.18M | 66.25M | 74.9M | 74.46M | 73.85M | 72.39M | 70.94M | 70.49M | 68.51M | 68.55M | 67.64M | 65.91M | 65.72M | 65M | 64.17M | 62.91M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $1.5B in buybacks, $276.68M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.98×
EV/EBIT
—
Peer median 32.54×
P/E (TTM)
—
Peer median 31.36×
Peer medians compare against the 27 similar-size Medical Instruments & Supplies companies (of 45 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Multiomics | $269,231,000 | $254,552,000 | $248,296,000 | $250,937,000 | — | — | — | — |
| Core Products | $197,631,000 | $196,502,000 | $192,061,000 | $199,230,000 | — | — | — | — |
| Sample Repository Solutions | $126,959,000 | $122,394,000 | $111,129,000 | $105,331,000 | — | — | — | — |
| B Medical Systems Sarl | — | $83,125,000 | $113,122,000 | $0 | — | — | — | — |
| Life Sciences Products | — | — | $305,184,000 | $199,230,000 | $199,606,000 | $129,759,000 | — | — |
| Life Sciences Services | — | — | $359,888,000 | $356,268,000 | $314,097,000 | $258,778,000 | — | — |
| Brooks Life Sciences Products | — | — | — | — | — | — | — | $106,146,000 |
| Brooks Life Sciences Services | — | — | — | — | — | — | — | $90,396,000 |
| Brooks Semiconductor Solutions Group | — | — | — | — | — | — | — | $435,018,000 |
| Life Sciences Products | — | — | — | — | — | — | $119,020,000 | — |
| Life Sciences Services | — | — | — | — | — | — | $215,159,000 | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $365,003,000 | $365,054,000 | $351,405,000 | $358,208,000 | $320,800,000 | $253,500,000 | $224,500,000 | $232,700,000 |
| Europe | $107,370,000 | $95,154,000 | $87,186,000 | $79,005,000 | $77,266,000 | $74,155,000 | $59,981,000 | $135,611,000 |
| China | $58,347,000 | $58,242,000 | $52,131,000 | $53,867,000 | $45,743,000 | $34,016,000 | — | — |
| United Kingdom | $35,388,000 | $27,204,000 | $26,660,000 | $30,258,000 | $31,539,000 | — | — | — |
| Asia Pacific | $23,280,000 | $21,320,000 | $25,630,000 | $32,829,000 | — | — | — | — |
| Other | $4,433,000 | $6,474,000 | $8,474,000 | — | — | — | — | — |
| Asia Pacific Other Than China | — | — | — | — | $34,485,000 | $24,192,000 | — | — |
| Asia Pacific and Other | — | — | — | — | $80,916,000 | $58,208,000 | $47,803,000 | $262,706,000 |
| Africa | — | — | — | $1,331,000 | $688,000 | — | — | — |
| North America | — | — | — | — | $323,982,000 | $256,174,000 | $226,395,000 | $233,243,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Service | $420,632,000 | $399,731,000 | $375,386,000 | $374,548,000 | $332,667,000 | $277,970,000 | $233,735,000 | $149,171,000 |
| Product | $173,189,000 | $173,717,000 | $176,100,000 | $180,950,000 | $181,036,000 | $110,567,000 | $100,444,000 | $482,389,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Sample Management Solutions | $27,550,000 | $11,106,000 | -$2,293,000 | $23,970,000 | — | — | — | — |
| Multiomics | -$11,937,000 | -$7,733,000 | -$13,337,000 | $5,032,000 | — | — | — | — |
| B Medical Systems Sarl | — | -$5,669,000 | $919,000 | $0 | — | — | — | — |
| Life Sciences Products | — | — | -$30,321,000 | $11,033,000 | $23,094,000 | -$3,041,000 | — | — |
| Life Sciences Services | — | — | -$14,722,000 | $10,784,000 | $22,659,000 | $2,859,000 | — | — |
| Brooks Life Sciences Products | — | — | — | — | — | $9,353,000 | -$1,835,000 | -$9,044,000 |
| Brooks Life Sciences Services | — | — | — | — | — | $28,832,000 | $22,466,000 | $12,839,000 |
| Brooks Semiconductor Solutions Group | — | — | — | — | — | $82,950,000 | $69,961,000 | $62,511,000 |
| Life Sciences Products | — | — | — | — | $23,094,000 | -$3,041,000 | -$20,876,000 | — |
| Life Sciences Services | — | — | — | — | $22,659,000 | $2,859,000 | $8,976,000 | — |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Multiomics | -4.4% | -3% | -5.4% | 2% | — | — | — | — |
| B Medical Systems Sarl | — | -6.8% | 0.8% | — | — | — | — | — |
| Life Sciences Products | — | — | -9.9% | 5.5% | 11.6% | -2.3% | — | — |
| Life Sciences Services | — | — | -4.1% | 3% | 7.2% | 1.1% | — | — |
| Brooks Life Sciences Products | — | — | — | — | — | — | — | -8.5% |
| Brooks Life Sciences Services | — | — | — | — | — | — | — | 14.2% |
| Brooks Semiconductor Solutions Group | — | — | — | — | — | — | — | 14.4% |
| Life Sciences Products | — | — | — | — | — | — | -17.5% | — |
| Life Sciences Services | — | — | — | — | — | — | 4.2% | — |
Key facts
CIK
933974
CUSIP
114340102
13F (30d)
238 filings
211 filers
Visit website
Investor relations